These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22974223)

  • 1. Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma.
    Commandeur S; van Drongelen V; de Gruijl FR; El Ghalbzouri A
    Cancer Sci; 2012 Dec; 103(12):2120-6. PubMed ID: 22974223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.
    Kitamura S; Maeda T; Yanagi T
    Biochem Biophys Res Commun; 2020 Oct; 531(3):396-401. PubMed ID: 32800552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
    Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
    Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
    Clayburgh DR; Gross ND; Proby C; Koide J; Wong MH
    Head Neck; 2013 Jan; 35(1):86-93. PubMed ID: 22495823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
    Jimeno A; Kulesza P; Wheelhouse J; Chan A; Zhang X; Kincaid E; Chen R; Clark DP; Forastiere A; Hidalgo M
    Br J Cancer; 2007 Mar; 96(6):952-9. PubMed ID: 17342092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Gold KA; Kies MS; William WN; Johnson FM; Lee JJ; Glisson BS
    Cancer; 2018 May; 124(10):2169-2173. PubMed ID: 29579331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
    Kivisaari AK; Kallajoki M; Ala-aho R; McGrath JA; Bauer JW; Königová R; Medvecz M; Beckert W; Grénman R; Kähäri VM
    Br J Dermatol; 2010 Oct; 163(4):726-35. PubMed ID: 20586780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
    Thelemann A; Petti F; Griffin G; Iwata K; Hunt T; Settinari T; Fenyo D; Gibson N; Haley JD
    Mol Cell Proteomics; 2005 Apr; 4(4):356-76. PubMed ID: 15657067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma.
    Frederick JW; Sweeny L; Hartman Y; Zhou T; Rosenthal EL
    Head Neck; 2016 Feb; 38(2):247-52. PubMed ID: 25270595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
    Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
    Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
    Dayekh K; Johnson-Obaseki S; Corsten M; Villeneuve PJ; Sekhon HS; Weberpals JI; Dimitroulakos J
    Mol Cancer Ther; 2014 Nov; 13(11):2559-71. PubMed ID: 25189541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma.
    Commandeur S; de Gruijl FR; Willemze R; Tensen CP; El Ghalbzouri A
    Exp Dermatol; 2009 Oct; 18(10):849-56. PubMed ID: 19469895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.